Dengue fever, COVID-19 (SARS-CoV-2), and antibody-dependent enhancement (ADE): a perspective (2020)
Source: Cytometry Part A. Unidade: IQ
Subjects: DENGUE, CORONAVIRUS, ANTICORPOS, COVID-19
ABNT
ULRICH, Henning e PILLAT, Micheli Mainardi e TÁRNOK, Attila. Dengue fever, COVID-19 (SARS-CoV-2), and antibody-dependent enhancement (ADE): a perspective. Cytometry Part A, v. 97A, p. 662–667, 2020Tradução . . Disponível em: https://doi.org/10.1002/cyto.a.24047. Acesso em: 11 set. 2024.APA
Ulrich, H., Pillat, M. M., & Tárnok, A. (2020). Dengue fever, COVID-19 (SARS-CoV-2), and antibody-dependent enhancement (ADE): a perspective. Cytometry Part A, 97A, 662–667. doi:10.1002/cyto.a.24047NLM
Ulrich H, Pillat MM, Tárnok A. Dengue fever, COVID-19 (SARS-CoV-2), and antibody-dependent enhancement (ADE): a perspective [Internet]. Cytometry Part A. 2020 ; 97A 662–667.[citado 2024 set. 11 ] Available from: https://doi.org/10.1002/cyto.a.24047Vancouver
Ulrich H, Pillat MM, Tárnok A. Dengue fever, COVID-19 (SARS-CoV-2), and antibody-dependent enhancement (ADE): a perspective [Internet]. Cytometry Part A. 2020 ; 97A 662–667.[citado 2024 set. 11 ] Available from: https://doi.org/10.1002/cyto.a.24047